Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Patients With Advanced Refractory Solid Tumors and Lymphoma

Next Previous
X
Search
Trial Profile

An Open-Label, Dose-Escalation/Expansion Phase 1 Study of ASP4132 Given Orally to Patients With Advanced Refractory Solid Tumors and Lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 4132 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Hodgkin's disease; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 08 Apr 2021 Status changed to discontinued.
    • 08 Apr 2021 Results published in the Investigational New Drugs.
    • 10 May 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top